These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

114 related items for PubMed ID: 18790238

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2. Different renal toxicity profiles in the association of cyclosporine and tacrolimus with sirolimus in rats.
    Lloberas N, Torras J, Alperovich G, Cruzado JM, Giménez-Bonafé P, Herrero-Fresneda I, Franquesa Ml, Rama I, Grinyó JM.
    Nephrol Dial Transplant; 2008 Oct; 23(10):3111-9. PubMed ID: 18469305
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4. A pharmacologically-based array to identify targets of cyclosporine A-induced toxicity in cultured renal proximal tubule cells.
    Sarró E, Jacobs-Cachá C, Itarte E, Meseguer A.
    Toxicol Appl Pharmacol; 2012 Jan 15; 258(2):275-87. PubMed ID: 22155090
    [Abstract] [Full Text] [Related]

  • 5. Fifteen years of clinical studies and clinical practice in renal transplantation: reviewing outcomes with de novo use of sirolimus in combination with cyclosporine.
    Kahan BD.
    Transplant Proc; 2008 Dec 15; 40(10 Suppl):S17-20. PubMed ID: 19100899
    [Abstract] [Full Text] [Related]

  • 6. [Nephrotoxicity of sirolimus: experimental and clinical data].
    Pallet N, Thervet E, Legendre C, Anglicheau D.
    Nephrol Ther; 2006 Sep 15; 2(4):183-90. PubMed ID: 16966063
    [Abstract] [Full Text] [Related]

  • 7. Targeted therapy of human osteosarcoma with 17AAG or rapamycin: characterization of induced apoptosis and inhibition of mTOR and Akt/MAPK/Wnt pathways.
    Gazitt Y, Kolaparthi V, Moncada K, Thomas C, Freeman J.
    Int J Oncol; 2009 Feb 15; 34(2):551-61. PubMed ID: 19148492
    [Abstract] [Full Text] [Related]

  • 8. Considerations in sirolimus use in the early and late post-transplant periods.
    Patel SJ, Elliott EN, Knight RJ, Gaber LW, Gaber AO.
    Expert Opin Drug Saf; 2009 Jul 15; 8(4):421-34. PubMed ID: 19522662
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. Chronic graft dysfunction and improvement by cytokine response modifier a protein transfection.
    Xiao Z, Shan J, Li C, Luo L, Feng L, Lu J, Li S, Long D, Li Y.
    Exp Clin Transplant; 2011 Oct 15; 9(5):302-9. PubMed ID: 21967255
    [Abstract] [Full Text] [Related]

  • 12. Nephrotoxic aspects of cyclosporine.
    Cattaneo D, Perico N, Gaspari F, Remuzzi G.
    Transplant Proc; 2004 Mar 15; 36(2 Suppl):234S-239S. PubMed ID: 15041344
    [Abstract] [Full Text] [Related]

  • 13. Antimyeloma activity of the orally bioavailable dual phosphatidylinositol 3-kinase/mammalian target of rapamycin inhibitor NVP-BEZ235.
    McMillin DW, Ooi M, Delmore J, Negri J, Hayden P, Mitsiades N, Jakubikova J, Maira SM, Garcia-Echeverria C, Schlossman R, Munshi NC, Richardson PG, Anderson KC, Mitsiades CS.
    Cancer Res; 2009 Jul 15; 69(14):5835-42. PubMed ID: 19584292
    [Abstract] [Full Text] [Related]

  • 14. Mammalian target of rapamycin inhibitors rapamycin and RAD001 (everolimus) induce anti-proliferative effects in GH-secreting pituitary tumor cells in vitro.
    Gorshtein A, Rubinfeld H, Kendler E, Theodoropoulou M, Cerovac V, Stalla GK, Cohen ZR, Hadani M, Shimon I.
    Endocr Relat Cancer; 2009 Sep 15; 16(3):1017-27. PubMed ID: 19509067
    [Abstract] [Full Text] [Related]

  • 15. Transplantation: toxicokinetics and mechanisms of toxicity of cyclosporine and macrolides.
    Serkova N, Christians U.
    Curr Opin Investig Drugs; 2003 Nov 15; 4(11):1287-96. PubMed ID: 14758767
    [Abstract] [Full Text] [Related]

  • 16. From bedside to bench drug-induced tubulointerstitial disease cyclosporine nephropathy study from models of cultured renal epithelial cells.
    Wu MS.
    Chang Gung Med J; 2007 Nov 15; 30(1):7-16. PubMed ID: 17477024
    [Abstract] [Full Text] [Related]

  • 17. Inter-laboratory comparison of human renal proximal tubule (HK-2) transcriptome alterations due to Cyclosporine A exposure and medium exhaustion.
    Jennings P, Aydin S, Bennett J, McBride R, Weiland C, Tuite N, Gruber LN, Perco P, Gaora PO, Ellinger-Ziegelbauer H, Ahr HJ, Kooten CV, Daha MR, Prieto P, Ryan MP, Pfaller W, McMorrow T.
    Toxicol In Vitro; 2009 Apr 15; 23(3):486-99. PubMed ID: 19159671
    [Abstract] [Full Text] [Related]

  • 18. Renal tubular expression of Toll-like receptor 4 in cyclosporine nephrotoxicity.
    Lim BJ, Hong SW, Jeong HJ.
    APMIS; 2009 Aug 15; 117(8):583-91. PubMed ID: 19664129
    [Abstract] [Full Text] [Related]

  • 19. The role of immunosuppressive drugs in aggravating renal ischemia and reperfusion injury.
    Gonçalves GM, Cenedeze MA, Feitoza CQ, de Paula CB, Marques GD, Pinheiro HS, de Paula Antunes Teixeira V, Antônia dos Reis M, Pacheco-Silva A, Câmara NO.
    Transplant Proc; 2007 Mar 15; 39(2):417-20. PubMed ID: 17362745
    [Abstract] [Full Text] [Related]

  • 20. Comparison of sirolimus plus tacrolimus versus sirolimus plus cyclosporine in high-risk renal allograft recipients: results from an open-label, randomized trial.
    Gaber AO, Kahan BD, Van Buren C, Schulman SL, Scarola J, Neylan JF, Sirolimus High-Risk Study Group.
    Transplantation; 2008 Nov 15; 86(9):1187-95. PubMed ID: 19005398
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 6.